Pages that link to "Q35579382"
Jump to navigation
Jump to search
The following pages link to Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. (Q35579382):
Displaying 50 items.
- Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral Reservoirs (Q33613493) (← links)
- Preventing infective complications in inflammatory bowel disease (Q34008766) (← links)
- Is There a Potential Role for Anti-tumor Necrosis Factor Therapy in Patients with Human Immunodeficiency Virus? (Q34074149) (← links)
- Efficacy of tumour necrosis factor-α antagonists in aphthous ulceration: review of published individual patient data. (Q34142185) (← links)
- Carla Task Force on Sarcopenia: propositions for clinical trials (Q35031618) (← links)
- Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies (Q35637506) (← links)
- The safety of etanercept for the treatment of plaque psoriasis. (Q35919214) (← links)
- TNFα Impairs Rhabdoviral Clearance by Inhibiting the Host Autophagic Antiviral Response. (Q36063179) (← links)
- A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier (Q36154001) (← links)
- Treatment of chronic inflammatory diseases with biologic agents: opportunities and risks for the elderly (Q36663141) (← links)
- Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients (Q36757744) (← links)
- Biologic agents in rheumatology: safety considerations (Q36780929) (← links)
- Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis (Q36847326) (← links)
- The use of TNF-alpha blocking agents in rheumatoid arthritis: an update (Q36916918) (← links)
- Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection (Q36958375) (← links)
- Invited commentary on David Fedson's article (Q37086826) (← links)
- Rheumatic conditions in human immunodeficiency virus infection (Q37138780) (← links)
- Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives (Q37211844) (← links)
- Sarcopenia in women with rheumatoid arthritis (Q37305184) (← links)
- Soybean-derived Bowman-Birk Inhibitor (BBI) Inhibits HIV Replication in Macrophages (Q37335524) (← links)
- Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients (Q37416404) (← links)
- TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy? (Q37433321) (← links)
- Use of infliximab in particular clinical settings: management based on current evidence (Q37506064) (← links)
- Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature (Q37671701) (← links)
- A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. (Q37814549) (← links)
- Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review (Q37892162) (← links)
- Biological therapies for inflammatory bowel disease: controversies and future options (Q37960183) (← links)
- Rheumatoid arthritis and the era of biologic therapy (Q37988317) (← links)
- Biologics in oral medicine: principles of use and practical considerations (Q37993932) (← links)
- Management of rheumatic disease with comorbid HBV or HCV infection. (Q38008173) (← links)
- The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease (Q38062336) (← links)
- Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis (Q38094015) (← links)
- Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy (Q38408897) (← links)
- Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. (Q38993250) (← links)
- Resistance to vaccinia virus is less dependent on TNF under conditions of heterologous immunity. (Q39914179) (← links)
- Hepatitis C virus treatment complicated by rheumatoid arthritis. (Q40622385) (← links)
- Exploring interaction of TNF and orthopoxviral CrmB protein by surface plasmon resonance and free energy calculation. (Q41142790) (← links)
- The use of ustekinumab in a patient with severe psoriasis and positive HBV serology (Q42204345) (← links)
- Infliximab in ankylosing spondylitis associated with chronic hepatitis B infection. Role of Lamivudine therapy (Q42728753) (← links)
- Etanercept Therapy in Patients with Psoriasis and Concomitant HCV Infection (Q42860236) (← links)
- Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases (Q43035871) (← links)
- Risk of infection during treatment with tumor necrosis factor-alpha inhibitors (Q43994517) (← links)
- Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B. (Q44464843) (← links)
- Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection (Q44807698) (← links)
- Secondary immunodeficiency in rheumatological diseases (Q44975901) (← links)
- Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs (Q46162379) (← links)
- Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients (Q46795207) (← links)
- Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice (Q47546977) (← links)
- The advent of the cytokine storm (Q47834672) (← links)
- A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C. (Q48163642) (← links)